Vasopressin and its immune effects in septic shock
- PMID: 20606409
- DOI: 10.1159/000318531
Vasopressin and its immune effects in septic shock
Abstract
Vasopressin is a stress hormone. However, vasopressin levels are inappropriately low in septic shock. Vasopressin stimulates AVPR1a, AVPR1b, AVPR2 and purinergic receptors. Vasopressin increases blood pressure by occupying AVPR1a receptors on vascular smooth muscle. An increase in ventricular afterload due to vasopressor administration limits ventricular systolic ejection, an effect that becomes increasingly important as systolic contractility is decreased. Stimulation of AVPR1a receptors may also decrease edemagenesis. Stimulation of AVPR1b by vasopressin releases ACTH and cortisol. AVPR2 stimulation increases retention of water by increasing cyclic AMP. Yet, vasopressin infusion may increase urine output, creatinine clearance and improve renal function in septic shock. Vasopressin has many effects on immune function such as altering cytokines, neuroimmunity, prostaglandins, humoral immunity and immune cells. For example, vasopressin decreases sepsis-induced pulmonary inflammation, could have renal anti-inflammatory effects and may decrease prostaglandin levels in a dose-dependent manner. Vasopressin may also modulate responses to stress by expression and release from immune cells. Interestingly, there are vasopressin receptors on immune cells. Many small clinical studies of vasopressin infusion in septic shock have shown that vasopressin infusion increases blood pressure, decreases requirements for norepinephrine and improves renal function. However, vasopressin could decrease coronary, cerebral and mesenteric perfusion. A multicenter trial of vasopressin versus norepinephrine in septic shock found no overall difference in mortality. Vasopressin may decrease mortality in patients with less severe septic shock. Vasopressin plus corticosteroid treatment may decrease mortality compared to corticosteroids plus norepinephrine. Potential mechanisms are that vasopressin plus corticosteroids beneficially alter immunity in septic shock.
2010 S. Karger AG, Basel.
Similar articles
-
Bench-to-bedside review: Vasopressin in the management of septic shock.Crit Care. 2011 Aug 11;15(4):226. doi: 10.1186/cc8224. Crit Care. 2011. PMID: 21892977 Free PMC article. Review.
-
Vasopressin in vasodilatory and septic shock.Curr Opin Crit Care. 2007 Aug;13(4):383-91. doi: 10.1097/MCC.0b013e328263885e. Curr Opin Crit Care. 2007. PMID: 17599007 Review.
-
The current management of septic shock.Minerva Med. 2008 Oct;99(5):431-58. Minerva Med. 2008. PMID: 18971911 Review.
-
Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock.Crit Care Med. 2009 Mar;37(3):811-8. doi: 10.1097/CCM.0b013e3181961ace. Crit Care Med. 2009. PMID: 19237882 Clinical Trial.
-
Terlipressin: vasopressin analog and novel drug for septic shock.Ann Pharmacother. 2006 Dec;40(12):2170-7. doi: 10.1345/aph.1H373. Epub 2006 Dec 5. Ann Pharmacother. 2006. PMID: 17148649 Review.
Cited by
-
Identification of a transcriptome profile associated with improvement of organ function in septic shock patients after early supportive therapy.Crit Care. 2018 Nov 21;22(1):312. doi: 10.1186/s13054-018-2242-3. Crit Care. 2018. PMID: 30463588 Free PMC article.
-
A New Role for Conivaptan in Ulcerative Colitis in Mice: Inhibiting Differentiation of CD4+T Cells into Th1 Cells.Dig Dis Sci. 2022 Aug;67(8):3683-3692. doi: 10.1007/s10620-021-07300-y. Epub 2021 Nov 9. Dig Dis Sci. 2022. PMID: 34751838
-
Inotropes and vasopressors: more than haemodynamics!Br J Pharmacol. 2012 Apr;165(7):2009-11. doi: 10.1111/j.1476-5381.2011.01776.x. Br J Pharmacol. 2012. PMID: 22074274 Free PMC article.
-
Pathophysiology of chikungunya virus infection associated with fatal outcomes.Cell Host Microbe. 2024 Apr 10;32(4):606-622.e8. doi: 10.1016/j.chom.2024.02.011. Epub 2024 Mar 12. Cell Host Microbe. 2024. PMID: 38479396 Free PMC article.
-
Argipressin for prevention of blood loss during liver resection: a study protocol for a randomised, placebo-controlled, double-blinded trial (ARG-01).BMJ Open. 2023 Aug 24;13(8):e073270. doi: 10.1136/bmjopen-2023-073270. BMJ Open. 2023. PMID: 37620260 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources